Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838614 | 0.92 | HDAC1 (0.66) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL5612900 | 0.90 | KCNK3 (0.69) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL3842896 | 0.90 | HDAC1 (0.54) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15907176 | 0.86 | KMT2A (0.61) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13023381 | 0.86 | HDAC1 (0.64) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13132582 | 0.86 | L3MBTL1 (0.73) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13132744 | 0.86 | L3MBTL1 (0.69) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13023357 | 0.85 | HDAC1 (0.57) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13065995 | 0.85 | PARP1 (0.55) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL13692719 | 0.85 | HDAC8 (0.52) | HDAC1HDAC2HDAC8HDAC6KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3417912-B1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| CN-105431436-A | Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2016-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | HDAC1 2400/4885HDAC2 2483/4885HDAC8 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.